These results demonstrate that CRISPR-Cas9-mediated knockout of Casp1 and Casp11 in keratinocytes, using LNPs for targeted delivery, effectively reduces the inflammatory response and mitigates psoriasis symptoms in the mouse psoriasis model, highlighting the potential of this strategy as a novel therapeutic approach for inflammatory skin diseases. Here, SCAF11 is linked to inflammatory skin disease.